| Breast carcinoma is a more common gynecoid malignant tumor in clinical, only less than cervical carcinoma and its incidence rate has gradually increased. Until now, the therapy methods of breast carcinoma are operation, chemotherapy and radiotherapy. But the prognosis of breast carcinoma depends on the behavior of lymph nodes and estrogen receptor, level of tumor differentiation, DNA Ploidy and so on. However the key to improve cure rate and survival rate is to diagnose earlier. So how to diagnose earlier and comprehensive treatment is becoming a focus of study. With monoclonal antibody technique developing, a new technique of radioimmunoimaging(RII) arised from the combination of the orientation of monoclonal antibody and the detectability in vitro of radionucide, which is not only being a successful combination of nuclear medicine and immunology but also opening up a new way of earlier diagnosis to tumor. At the same, medical workers have devised an other new technique of radioimmunotherapy(RIT) to the therapy of tumor, which may become the major therapeutic tool besides those three methods in the future.So in our study, cell culture, the model of nude mice bearing MCF-7 cell and Rn and RIT with 131I-Anti-CEA,TPS McAb in that model were used to observe the feasibility of imaging and therapy by RII and RIT in nude mice bearing tumor cell, in order to provide a basis for the application of RII and RIT in the diagnosis and treatment to breast carcinoma.The first part is a research of RII with 131I-Anti-CEA,TPS McAb in nude mice bearing MCF-7 cell. Nude mice were divided into 4 groups with equal numbers to receive single injection of 3.7MBq131I-Anti-CEA, 3.7MBq131I-Anti-TPS, 3.7MBq131I-Anti-CEA+TPS ( those three therapy group) or 3.7MBq131I-mIgG (control group) from caudal vein and then RII were performed at the 24th, 48th, 96th and 120th hour by SPECT. We observed that the positive rates of those three therapy groups were respectively 50%, 58% and 91% and higher than that of control group(p<0.05). Furthermore, 131I-Anti-CEA+TPS group (91%) was superior to 131I-Anti-CEA(50%) and 131I-Anti-TPS group(58%). Meanwhile, at the 48th, 96th and 120th hour after imaging, we put two mice to death in each groups and got bowel and neoplasm in order to gain Cpm, T/NT and %ID/g. The results were as following. Selective accumulation of 131I-Anti-CEA-TPS, 131I-Anti-CEA and 131I-Anti-TPS were observed in tumor site of nude mice bearing MCF-7 and the figure of T/NT increased gradually until higher than 2.5 at 96th hour after injection in three therapy groups. Moreover, T/NT and %ID/g values in three therapy groups were significantly higher than those in control group and the two values in 131I-Anti-CEA+TPS group were similarly higher than those in 131I-Anti-CEA and 131I-Anti-TPS groups(p<0.05). But there was no significant difference about the two values between 131I-Anti-CEA and I31I-Anti-TPS groups, and figures of T/NT and %ID/g in control group and normal tissue decreased with time. We also found that there was no significant difference about half life in vivo of labeled antibody between therapy groups and control. However, existing time in vivo of labeled antibody in 4 groups was respectively 180hours(131I-Anti-CEA), 168hours(131I-Anti-TPS), 196hours(131I-Anti-CEA-TPS) and72hours(13lI-mIgG). The time of therapy groups was longer than that of contral(p<0.05).The second part, we investigated the effect of 131I-Anti-CEA McAb innude mice bearing MCF-7 cell by RIT. The nude mice were divided into 3 groups: 131I-mIgG 18.5MBq (control group), 131I-Anti-CEA 3.7MBq and 18.5MBq (therapy group) and 131I-mIgG or 131I-Anti-CEA were directly injected to tumor mass which diameter was about 0.8cm. After breeding for 6 weeks, we discovered that there is no obvious change about mental state, activity, skin status, body weight and the dose of diet and drinking of nude mice in therapy groups. Yet nude mice were depressed, eat less and lost weight later in control group because of the fast growth of carcino...
|
PDF Full Text Request